Under the terms of the agreement, the financial details of which were not disclosed, Bio-Rad will have the right to develop the heparin binding protein marker for use on its proprietary laboratory instruments worldwide.
Under the terms of the agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally. Additional terms of the deal were not disclosed.
With FDA clearance, the test, which had been available outside the US, will now become available in the US.
Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.
The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.
Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.
In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.